• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

raw material change passive medical device
Wednesday, 03 June 2020 / Published in Medical Device

NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

On 19.05.2020, the NMPA (National Medical Products Administration) addressed the guidance notes (No.33-2020) for NMPA Legal Agents to formulate risk control measures due to the changes in raw materials used for manufacturing passive medical devices. With this guidance, NMPA Legal Agents should be in a better position to determine if it is necessary to apply for registration approval for the changes.

According to the guidance notes, the NMPA Legal Agent is responsible to evaluate and determine if the raw material changes would initiate any biological hazards, as well as consider whether there will be an impact to the chemical properties and physical performance of the parts or the medical device itself.

The common changes in the raw materials include, but are not limited to the following:

  • Change of the type;
  • Change of the composition and ratio; and
  • Change of the preparation process.

The NMPA Legal Agent should always formulate an effective risk control plan and evaluate the effectiveness of the risk control measures. After taking risk control measures, any remaining risks should be evaluated using the criteria as specified in the risk management plan. If the residual risk is considered to be unacceptable, further risk control measures or risk-benefit analysis should be taken until the raw material has been accepted or rejected.

This guidance document does not act as an enforced regulation, and does not stipulate whether registration review and approval is required for material changes.

By Jacky Li. Contact Cisema to learn more.

Tagged under: medical device raw materials, passive medical devices, raw material change

What you can read next

Supervision and administration of medical devices
Supervision and administration of medical device – sampling inspections finds 12 product failures
China medical device standards management 2022
China medical device standards management 2022 annual report issued
GB9706.1-2020 implementation explained
GB9706.1-2020 implementation explained by NMPA

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Physicochemical characterization of nanomaterials

    Physicochemical characterization of nanomaterials used in medical devices – New guidelines issued

    Physicochemical characterization of nanomateria...
  • Registration of disposable light-proof infusion sets in China

    Registration of disposable light-proof infusion sets in China – Amended guidelines issued

    Registration of disposable light-proof infusion...
  • Registration of disposable blood separation devices in China

    Registration of disposable blood separation devices in China – Amended guidelines issued

    Registration of disposable blood separation dev...
  • Registration of disposable infusion devices in China

    Registration of disposable infusion devices in China – Amended guidelines issued

    Registration of disposable infusion devices in ...
  • Registration of blood dialyzers in China

    Registration of blood dialyzers in China – Amended guidelines issued

    Registration of blood dialyzers in China shall ...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP